Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neisseria meningitidis group B factor H binding protein subfamily B
- Development stage
- Unknown
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Neisseria meningitidis group B factor H binding protein subfamily B is a recombinant protein vaccine candidate developed by Assistance Publique - Hôpitaux de Paris (AP-HP) for the prevention of meningococcal group B infection. The vaccine consists of the subfamily B (also known as variant 1) of the factor H binding protein (fHbp), a surface lipoprotein that allows *Neisseria meningitidis* to evade the host's immune system by binding human factor H, a down-regulator of the alternative complement pathway. By inducing the production of antibodies that block this interaction, the vaccine facilitates complement-mediated bactericidal activity against the pathogen. It has been investigated in Phase 1 clinical trials to evaluate its safety and immunogenicity profile in healthy adults, typically formulated with an aluminum hydroxide adjuvant.
- Other names
- fHbp subfamily BfHbp variant 1recombinant Neisseria meningitidis group B factor H binding protein subfamily B
02
Targets
CFH (Complement factor H)fHbp (Factor H-binding protein)
Beyond the preview
Go deeper on neisseria meningitidis group B factor H binding protein subfamily B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neisseria meningitidis group B factor H binding protein subfamily B.